David D. Ho

The paper develops a monoclonal antibody panel to track antigenic evolution of SARS-CoV-2 JN.1 subvariants and identifies differences in antibody-evasion profiles between JN.1 and BA.3.2 lineages.

This study evaluates antibody evasion and ACE2 receptor engagement of SARS-CoV-2 variant RW.1.1, finding reduced receptor binding but no increased serum resistance compared to other variants.

This study finds that young children have lower neutralizing antibody titers against BA.3.2.2 compared to adults, despite similar titers against dominant variants, suggesting age-related differences in susceptibility.

This study generates 19 human monoclonal antibodies to track antigenic evolution of H5N1 clade 2.3.4.4b, identifying epitope-specific neutralization patterns and antigenic differences between viral genotypes.

This study evaluates the effectiveness of LP.8.1-targeted mRNA vaccines in boosting neutralizing antibodies and reducing immune imprinting from ancestral SARS-CoV-2 strains.

This study identifies monoclonal antibodies with ACE2-like catalytic activity that may contribute to post-acute sequelae of COVID-19.

This study evaluates VYD2311, a new monoclonal antibody, showing it neutralizes multiple SARS-CoV-2 variants more effectively than pemivibart, making it a potential candidate for immunocompromised individuals.

This study compares antibody evasion and receptor binding of SARS-CoV-2 subvariants, finding that LP.8.1.1 has high ACE2 affinity, while NB.1.8.1 and XFG show greater antibody evasion.

This study optimizes a human monoclonal antibody to enhance its neutralization of SARS-CoV-2 variants, including subvariants XEC and LP.8.1, through structural analysis and engineering.

This study assesses whether 2025 COVID-19 vaccines need updating by testing neutralizing antibody titers against emerging variants in individuals vaccinated with KP.2-based mRNA vaccines.

This study evaluates the antibody evasion of SARS-CoV-2 subvariants KP.3.1.1 and XEC compared to their parental variants, finding increased resistance to neutralization by sera and antibodies targeting the spike protein.

This study evaluates KP.2-based monovalent mRNA vaccines and finds they robustly boost neutralizing antibodies against current SARS-CoV-2 variants, including KP.3.1.1 and XEC.

The paper reports the cryo-EM structure of H5N1 hemagglutinin showing an auto-glycan from N169 binds the receptor-binding site, highlighting auto-glycan recognition in zoonotic transmission.

This study develops a monoclonal antibody that broadly neutralizes multiple SARS-CoV-2 variants, including JN.1, and shows its protective efficacy in mice.

This study examines how recurrent spike mutations in SARS-CoV-2 JN.1 sublineages affect immune evasion, ACE2 affinity, and infectivity, identifying growth advantages in specific sublineages.

This study shows that neutralizing antibodies against SARS-CoV-2 variants remain stable for three months after an XBB.1.5 mRNA vaccine booster.

The paper shows that an infectious intermediate form of SARS-CoV-2 persists in vitro after protease inhibitor treatment, potentially explaining viral rebound in patients.

This study evaluates pemivibart's neutralizing activity against recent SARS-CoV-2 JN.1 sublineages and finds it has substantially reduced potency against KP.3.1.1.

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

XBB.1.5 monovalent mRNA vaccine booster significantly increases neutralizing antibodies against multiple SARS-CoV-2 variants in both uninfected and previously infected individuals.